Oncology Archives | Page 2 of 2 | Report Store

Type 1 Diabetes KOL Interview – UK

$599.00

This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes.

January 8, 2020

Find out more

Type 1 Diabetes KOL Interview – US, Midwest

$599.00

This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market.

January 8, 2020

Find out more

Triple-Negative Breast Cancer KOL Interview – UK

$599.00

A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 31, 2019

Find out more

2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

$4,750.00

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ovarian cancer, such as Zejula, Lynparza and veliparib, as well as a follow-up update for KRAS-targeted drug AMG 510 for colorectal cancer, and CDK4/6-inhibitors, Kisqali and Verzenio, for breast cancer. Key pipeline updates for more established drugs were highly featured including Keytruda for…

October 18, 2019

Find out more

Bladder Cancer KOL Interview – US

$599.00

A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

May 31, 2019

Find out more

2018 Biomedtracker Datamonitor Healthcare Post-ASH Report

$599.00

The 60th American Society of Hematology (ASH) Annual Meeting and Exposition was held in San Diego, CA from December 1-4, 2018.

January 3, 2019

Find out more